BiomX reports positive Phase 2 results for BX211, showing over 40% wound size reduction in diabetic foot osteomyelitis patients. Nature Communications publishes data on BX004, demonstrating a 500-fold bacterial reduction. Phase 2b trial of BX004 in Cystic Fibrosis patients has begun, with FDA feedback expected in H2 2025 and results in Q1 2026. Financially, BiomX’s cash balance is $15.2 million as of June 30, 2025. Research and development expenses were $5.0 million, and general and administrative expenses were $2.4 million in the second quarter of 2025, resulting in a net loss of $6.0 million. BiomX will host a conference call and webcast on August 13, 2025, at 8 AM ET.

Read more at GlobeNewswire: BiomX Reports Second Quarter 2025 Financial Results and